Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refrac...
Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )
21 Sep 2021
New MM patients with high levels of circulating tumour cells distinguished by in...
Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands
New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation ( Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands )
21 Sep 2021
Novel therapies in multiple myeloma
Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021
Disparities in myeloma: Closing the gap
Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Disparities in myeloma: Closing the gap ( Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple mye...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
19 Sep 2021
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL am...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
19 Sep 2021
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed...
Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, U...
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )
18 Sep 2021
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...
Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )
14 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Should every transplant eligible NDMM patient receive a transplant?
Prof Morie Gertz - Mayo Clinic, Rochester, USA
Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )
14 Sep 2021
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-ta...
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021